Financial Statements 97 8 INTANGIBLE ASSETS Product marketing and Software distribution Other development Goodwill rights intangibles costs Total $m $m $m $m $m Cost At 1 January 2003 1,254 2,537 398 352 4,541 Additions - separately acquired 1 38 32 61 132 Additions - internally developed 43 43 Exchange and other movements 52 382 5 6 445 At 31 December 2003 1,307 2,957 435 462 5,161 Additions separately acquired 42 40 74 156 Additions internally developed 59 59 Exchange and other movements 18 203 2 1 224 At 31 December 2004 1,325 3,202 477 596 5,600 Additions separately acquired 43 57 76 176 Additions internally developed Exchange and other movements 45 442 31 23 541 At 31 December 2005 1,280 2,803 503 649 5,235 Amortisation and impairment losses At 1 January 2003 310 827 275 242 1,654 Amortisation for the year 204 28 64 296 Impairment charge 7 7 Exchange and other movements 14 155 8 177 At 31 December 2003 324 1,186 318 306 2,134 Amortisation for year 220 25 61 306 Impairment charge 10 10 Exchange and other movements 2 101 8 5 100 At 31 December 2004 336 1,507 335 372 2,550 Amortisation for year 214 19 39 272 Exchange and other movements 9 288 3 5 299 At 31 December 2005 327 1,433 357 406 2,523 Net book value At 31 December 2003 983 1,771 117 156 3,027 At 31 December 2004 989 1,695 142 224 3,050 At 31 December 2005 953 1,370 146 243 2,712 Amortisation and impairment charges Amortisation and impairment charges are recognised in selling, general and administrative expenses in the income statement.
The impairment in 2004 was in relation to the write-off of goodwill associated with Exanta.
The impairment in 2003 was in respect of amounts capitalised in relation to collaboration arrangements with NicOx and in respect of ANG453, which were terminated.
For the purposes of impairment testing of goodwill, the Group is regarded as a single, cash-generating unit.
The cash-generating units recoverable amount is based on value in use using projections of the Groups performance over ten years, a period reflecting the patent-protected lives of our current products.
A risk-adjusted discount rate of 12% has been applied to the projections.
Material assets Carrying Remaining value amortisation Description $m period Goodwill in the US Goodwill 707 Not amortised Intangible assets arising from joint venture with Merck Product, marketing and distribution rights 368 8 and 12 years Advance payment Product, marketing and distribution rights 668 13 years These assets are associated with the restructuring of the joint venture with Merck & Co. Inc.
